GSK: priority review for ViiV HIV drug
(CercleFinance.com) - ViiV Healthcare, GlaxoSmithKline's HIV treatment subsidiary, announced on Tuesday that the Food and Drug Administration (FDA) has granted priority review to its application for cabotegravir.
Cabotegravir, a long-acting injectable solution, is intended to prevent HIV infection in men who have sexual relations with men, cisgender women and transgender women who have been exposed to the virus.
The FDA is expected to make its decision on 24 January 2022, GSK said in a statement.
ViiV Healthcare also announced on Tuesday that it had signed an exclusive licensing agreement with Japan's Shionogi for the development of a new generation integrase inhibitor that would enable ultra-prolonged action.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
Cabotegravir, a long-acting injectable solution, is intended to prevent HIV infection in men who have sexual relations with men, cisgender women and transgender women who have been exposed to the virus.
The FDA is expected to make its decision on 24 January 2022, GSK said in a statement.
ViiV Healthcare also announced on Tuesday that it had signed an exclusive licensing agreement with Japan's Shionogi for the development of a new generation integrase inhibitor that would enable ultra-prolonged action.
Copyright (c) 2021 CercleFinance.com. All rights reserved.